Attached files
| file | filename |
|---|---|
| 8-K - 8-K - ANI PHARMACEUTICALS INC | a13-15313_18k.htm |
| EX-10.2 - EX-10.2 - ANI PHARMACEUTICALS INC | a13-15313_1ex10d2.htm |
| EX-10.1 - EX-10.1 - ANI PHARMACEUTICALS INC | a13-15313_1ex10d1.htm |
| EX-99.1 - EX-99.1 - ANI PHARMACEUTICALS INC | a13-15313_1ex99d1.htm |
| EX-99.2 - EX-99.2 - ANI PHARMACEUTICALS INC | a13-15313_1ex99d2.htm |
Exhibit 16.1
|
|
Deloitte & Touche LLP |
|
|
111 S. Wacker Drive |
|
|
Chicago, IL 60606 |
|
|
USA |
|
|
|
|
|
Tel: +1 312 486 1000 |
|
|
Fax: +1 312 486 1486 |
|
|
www.deloitte.com |
June 20, 2013
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549-7561
Dear Sirs/Madams:
We have read Item 4 of BioSante Pharmaceuticals, Inc.’s Form 8-K dated June 20, 2013, and have the following comments:
1. We agree with the statements made in the first, second, third and fifth paragraphs of Item 4.01.
2. We have no basis on which to agree or disagree with the statements made in the fourth paragraph of Item 4.01.
Yours truly,
/s/ Deloitte & Touche LLP
|
|
Member of |
|
|
Deloitte Touche Tohmatsu Limited |